Price$0.19+0.00 (+0.00%)
2026-03-042026-06-05
News · 26 weeks22+100%
2025-12-142026-06-07
Mix290d
- SEC Filings1(50%)
- Other1(50%)
Latest news
25 items- PRNew Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric VitiligoHORSHAM, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company"), a global leader in excimer laser therapy dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today highlighted the publication of a landmark multicenter, prospective, randomized controlled trial in the Journal of the American Academy of Dermatology demonstrating that STRATA's 308-nm excimer laser, when combined with oral JAK inhibitors, produces unprecedented repigmentation outcomes in pediatric patients with progressive vitiligo — with a favorable safety profile across all 188 children enrolled over a 48-week treatment
- SECSEC Form 10-K filed by Strata Skin Sciences Inc.10-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form EFFECT filed by Strata Skin Sciences Inc.EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form EFFECT filed by Strata Skin Sciences Inc.EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form EFFECT filed by Strata Skin Sciences Inc.EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form 15-12G filed by Strata Skin Sciences Inc.15-12G - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form POS AM filed by Strata Skin Sciences Inc.POS AM - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form POS AM filed by Strata Skin Sciences Inc.POS AM - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form POS AM filed by Strata Skin Sciences Inc.POS AM - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECSEC Form S-8 POS filed by Strata Skin Sciences Inc.S-8 POS - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- PRSTRATA Skin Sciences Confirms Nasdaq DelistingHORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and confirms that trading of the Company's common stock has been suspended from trading on The Nasdaq Capital Market ("Nasdaq") at the opening of business on February 19, 2026. The Company also expects to file a Form 15 with the SEC on or about March
- SECSEC Form 25 filed by Strata Skin Sciences Inc.25 - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- PRJohns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer LaserHORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins' ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the departm
- PRSTRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque PsoriasisHORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the Journal of Drugs in Dermatology by investigators from Georgetown University School of Medicine and the Department of Dermatology at MedStar Washington Hospital Center, the analysis evaluated clinical trials assessing the efficacy of the 308 nm excimer laser for plaque psoriasis. Across the included studies,
- SECStrata Skin Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECStrata Skin Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- SECStrata Skin Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
- PRSTRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in MexicoHORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting growing adoption of this innovative acne treatment modality by dermatologists in the region. Key Highlights STRATA showcased XTRAC®, the leading targeted UVB excimer laser for psoriasis, vitiligo, and other skin conditions
- INSIDERDirector Rubinstein Samuel sold $18,804 worth of shares (14,094 units at $1.33) and bought $7,028 worth of shares (5,000 units at $1.41), decreasing direct ownership by 51% to 8,766 units (SEC Form 4)4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
SSKN FAQ
6 questionsWhat does Strata Skin Sciences Inc. do?
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally...Where does SSKN stock trade?
Strata Skin Sciences Inc. (SSKN) is listed on NASDAQ.What sector and industry is SSKN in?
Strata Skin Sciences Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Strata Skin Sciences Inc. go public?
Strata Skin Sciences Inc. (SSKN) completed its IPO in 2005.What companies are similar to SSKN?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare SSKN side-by-side with any of them on Quantisnow.How can I track SSKN on Quantisnow?
Quantisnow aggregates Strata Skin Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SSKN to receive live email and push alerts on every new disclosure.